Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Protein and peptide therapeutics require parenteral administration, which can be a deterrent
to medication adherence. For this reason, there have been extensive efforts to develop …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for
the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …